U.S. markets closed

Northwest Biotherapeutics, Inc. (NWBO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.3650-0.0300 (-2.15%)
At close: 3:59PM EDT

Northwest Biotherapeutics, Inc.

4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
United States
240 497 9024
http://www.nwbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Ms. Linda F. Powers J.D.Chairperson, CEO, Pres, Acting CFO & Chief Accounting Officer602kN/A1956
Dr. Alton L. BoyntonFounder, Chief Scientific Officer, Sec. & Director345kN/A1945
Dr. Marnix L. Bosch M.B.A., Ph.D., MBAChief Technical Officer397kN/A1959
Ms. Jean M. DavisChief Information Officer258.78kN/A1972
Mr. Leslie J. GoldmanSr. VP & Gen. Counsel442kN/A1945
Mr. David InnesVP of Investor RelationsN/AN/AN/A
Mr. Pankaj R. Shah C.A., CPAFinancial ControllerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L that is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Corporate Governance

Northwest Biotherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.